IDH-mutant and 1p/19q-codeleted oligodendroglioma
MONDO:0859592An anaplastic oligodendroglioma that has material basis in IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).
2842 clinical trials for this condition and its sub-types, 10 tagged with IDH-mutant and 1p/19q-codeleted oligodendroglioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of IDH-mutant and 1p/19q-codeleted oligodendroglioma
-
New hope for brain tumor patients: targeted drug shows promise in phase 3 trial
Disease control Recruiting nowThis study tests a drug called safusidenib in people with a type of brain tumor (glioma) that has a specific gene mutation (IDH1). The trial has three parts: one for recurrent tumors, one for high-risk tumors after standard treatment, and one for a specific tumor type after surge…
Phase 3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New cell therapy trial hopes to tackle recurrent brain cancer
Disease control Recruiting nowThis early-stage trial is testing a personalized cell therapy for adults with recurrent oligodendroglioma, a type of brain tumor. The treatment involves taking a patient's own immune cells and stem cells, modifying them in the lab, and giving them back to fight the tumor. The mai…
Phase 1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Personalized drug test aims to outsmart refractory brain tumors
Knowledge-focused Recruiting nowThis study tests a lab technique called pharmacoscopy that analyzes a patient's tumor tissue to find which drugs might work best for them. It includes 40 adults with various aggressive or rare brain tumors that have not responded to standard treatments. The main goal is to see if…
Phase 2 • Sponsor: University of Zurich • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:00 UTC